Nanobiotix Management

Management criteria checks 1/4

Nanobiotix's CEO is Laurent Levy, appointed in Mar 2003, has a tenure of 21.67 years. total yearly compensation is €3.40M, comprised of 12.1% salary and 87.9% bonuses, including company stock and options. directly owns 2.4% of the company’s shares, worth €3.79M. The average tenure of the management team and the board of directors is 5.3 years and 2 years respectively.

Key information

Laurent Levy

Chief executive officer

€3.4m

Total compensation

CEO salary percentage	12.1%
CEO tenure	21.7yrs
CEO ownership	2.4%
Management average tenure	5.3yrs
Board average tenure	2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Laurent Levy's remuneration changed compared to Nanobiotix's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-€33m
Mar 31 2024	n/a	n/a	-€37m
Dec 31 2023	€3m	€411k	-€40m
Sep 30 2023	n/a	n/a	-€49m
Jun 30 2023	n/a	n/a	-€59m
Mar 31 2023	n/a	n/a	-€58m
Dec 31 2022	€1m	€380k	-€57m
Sep 30 2022	n/a	n/a	-€50m
Jun 30 2022	n/a	n/a	-€43m
Mar 31 2022	n/a	n/a	-€45m
Dec 31 2021	€4m	€380k	-€47m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€43m
Mar 31 2021	n/a	n/a	-€39m
Dec 31 2020	€818k	€330k	-€34m
Sep 30 2020	n/a	n/a	-€41m
Jun 30 2020	n/a	n/a	-€48m
Mar 31 2020	n/a	n/a	-€49m
Dec 31 2019	€2m	€330k	-€51m
Sep 30 2019	n/a	n/a	-€46m
Jun 30 2019	n/a	n/a	-€42m
Mar 31 2019	n/a	n/a	-€36m
Dec 31 2018	€1m	€300k	-€30m
Sep 30 2018	n/a	n/a	-€28m
Jun 30 2018	n/a	n/a	-€27m
Mar 31 2018	n/a	n/a	-€26m
Dec 31 2017	€861k	€253k	-€26m

Compensation vs Market: Laurent's total compensation ($USD3.56M) is above average for companies of similar size in the German market ($USD782.05K).

Compensation vs Earnings: Laurent's compensation has increased whilst the company is unprofitable.

CEO

Laurent Levy (51 yo)

21.7yrs

Tenure

€3,396,084

Compensation

Mr. Laurent Lévy, Ph.D. has been the President of the Executive Board at Nanobiotix S.A. since May 27, 2004 and its Chief Executive Officer since March 2003. Mr. Lévy has a thorough understanding of the te...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Laurent Levy	Co-Founder	21.7yrs	€3.40m	2.4% € 3.8m
Bart Van Rhijn	Chief Financial & Business Officer and Member of Executive Board	3.4yrs	€1.50m	0% € 0
Anne-Juliette Hermant	Chief People Officer & Member of Executive Board	5.3yrs	€801.96k	0.30% € 466.2k
Louis Kayitalire	Chief Medical Officer	1.2yrs	€500.80k	no data
Earl Bergey	Co-Founder	21.8yrs	no data	no data
Craig West	Senior Vice President of Investor Relations	no data	no data	no data
Brandon Owens	VP of Strategic Marketing & Corporate Communication	no data	no data	no data
Margaret Galluzzi	VP & Global Head of Clinical Operations	5.8yrs	no data	no data
Leonard Farber	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board	2.8yrs	no data	no data

5.3yrs

Average Tenure

51yo

Average Age

Experienced Management: 5NRA's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Leonard Farber	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board	no data	no data	no data
Enno Spillner	Independent Member of Supervisory Board	10.4yrs	€50.00k	no data
Gary Phillips	Independent Chairman of Supervisory board	3.5yrs	€63.00k	no data
Silvia Formenti	Member of Scientific Advisory Board	2yrs	no data	no data
Alain Herrera	Independent Member of Supervisory Board	11.4yrs	€35.00k	no data
Anne-Marie Graffin	Independent Vice Chairman of the Supervisory Board	10.9yrs	€42.00k	no data
Hisham Mehanna	Member of Scientific Advisory Board	2yrs	no data	no data
Stephane Champiat	Member of Scientific Advisory Board	2yrs	no data	no data
Jean Bourhis	Member of Scientific Advisory Board	2yrs	no data	no data
Thierry Baere	Member of Scientific Advisory Board	2yrs	no data	no data
Christophe Tourneau	Member of Scientific Advisory Board	2yrs	no data	no data
Nancy Lee	Member of Scientific Advisory Board	2yrs	no data	no data

2.0yrs

Average Tenure

60.5yo

Average Age

Experienced Board: 5NRA's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Nanobiotix Management

Management criteria checks 1/4

Key information

Recent management updates

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Recent updates

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age